126 related articles for article (PubMed ID: 2516705)
1. Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism.
Prezelj J; Kocijancic A; Andolsek L
Gynecol Endocrinol; 1989 Dec; 3(4):281-8. PubMed ID: 2516705
[TBL] [Abstract][Full Text] [Related]
2. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.
Carmina E; Lobo RA
Obstet Gynecol; 1991 Nov; 78(5 Pt 1):845-9. PubMed ID: 1833685
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
4. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
Keleştimur F; Everest H; Unlühizarci K; Bayram F; Sahin Y
Eur J Endocrinol; 2004 Mar; 150(3):351-4. PubMed ID: 15012621
[TBL] [Abstract][Full Text] [Related]
5. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission.
Carmina E; Lobo RA
Fertil Steril; 1998 Jun; 69(6):1075-9. PubMed ID: 9627295
[TBL] [Abstract][Full Text] [Related]
6. Role of androgens in menstrual disorders of nonhirsute and hirsute women, and the effect of glucocorticoid therapy on androgen levels in hirsute hyperandrogenic women.
Ho Yuen B; Mincey EK
Am J Obstet Gynecol; 1983 Jan; 145(2):152-7. PubMed ID: 6401396
[TBL] [Abstract][Full Text] [Related]
7. Hirsutism--a low dose spironolactone therapy.
Vĕtr M
Acta Univ Palacki Olomuc Fac Med; 1989; 122():239-45. PubMed ID: 2530821
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.
Messina M; Manieri C; Biffignandi P; Massucchetti C; Novi RF; Molinatti GM
J Endocrinol Invest; 1983 Feb; 6(1):23-7. PubMed ID: 6404979
[TBL] [Abstract][Full Text] [Related]
9. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
10. Menstrual history as a determinant of current bone density in young hirsute women.
Castelo-Branco C; Pons F; Martinez de Osaba MJ; Garrido J; Fortuny A
Metabolism; 1996 Apr; 45(4):515-8. PubMed ID: 8609841
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
Andreyko JL; Monroe SE; Jaffe RB
J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
[TBL] [Abstract][Full Text] [Related]
12. The grade of hirsutism correlated to serum androgen levels and hormonal indices.
Ruutiainen K; Erkkola R; Kaihola HL; Santti R; Irjala K
Acta Obstet Gynecol Scand; 1985; 64(8):629-33. PubMed ID: 2938400
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism.
Erenus M; Gürbüz O; Durmuşoğlu F; Demirçay Z; Pekin S
Fertil Steril; 1994 Apr; 61(4):613-6. PubMed ID: 8150100
[TBL] [Abstract][Full Text] [Related]
14. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
15. The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women.
Gregoriou O; Bakas P; Konidaris S; Papadias K; Mathiopoulos D; Creatsas G
Gynecol Endocrinol; 2000 Oct; 14(5):369-73. PubMed ID: 11109976
[TBL] [Abstract][Full Text] [Related]
16. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
[TBL] [Abstract][Full Text] [Related]
17. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
[TBL] [Abstract][Full Text] [Related]
18. Ovarian 17-ketosteroid reductase deficiency as a possible cause of polycystic ovarian disease.
Toscano V; Balducci R; Bianchi P; Mangiantini A; Sciarra F
J Clin Endocrinol Metab; 1990 Aug; 71(2):288-92. PubMed ID: 2166066
[TBL] [Abstract][Full Text] [Related]
19. Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
Evron S; Shapiro G; Diamant YZ
Fertil Steril; 1981 Oct; 36(4):468-71. PubMed ID: 6793406
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone].
Devoto E; Aravena L; Ríos R
Rev Med Chil; 2000 Aug; 128(8):868-75. PubMed ID: 11129548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
